Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G, Assoumou L, de Castro N, Post FA, Curran A, Rusconi S, De Wit S, Stephan C, Raffi F, Johnson M, Masia M, Vera J, Jones B, Grove R, Fletcher C, Duffy A, Morris K, Pozniak A; NEAT ID Foundation and the WISARD study group. Moyle G, et al. Among authors: masia m. Lancet HIV. 2024 Mar;11(3):e156-e166. doi: 10.1016/S2352-3018(23)00292-8. Lancet HIV. 2024. PMID: 38417976 Clinical Trial.
Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team. Imaz A, et al. Among authors: masia m. Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18. Antivir Ther. 2013. PMID: 22805174 Clinical Trial.
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, et al. Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12. Int J Epidemiol. 2012. PMID: 23148105 Free PMC article.
Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.
Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group. Suárez-García I, et al. HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6. HIV Med. 2014. PMID: 24007468 Free article.
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial.
Llibre JM, Alvarez H, Antela A, Toro J, Payeras A, Pérez-Elías MJ, Imaz A, Masià M, Pérez-Alvarez N, Burgos J, Clotet B; Members of the Nuke-Out Study. Llibre JM, et al. Among authors: masia m. J Antimicrob Chemother. 2016 May;71(5):1346-51. doi: 10.1093/jac/dkv461. Epub 2016 Jan 23. J Antimicrob Chemother. 2016. PMID: 26803719 Clinical Trial.
Executive summary of the consensus document on osteoporosis in HIV-infected individuals.
Negredo E, Domingo P, Gutiérrez F, Galindo MJ, Knobel H, Lozano F, Martínez E, Masiá M, Polo R, Estrada V. Negredo E, et al. Among authors: masia m. Enferm Infecc Microbiol Clin (Engl Ed). 2018 May;36(5):312-314. doi: 10.1016/j.eimc.2017.03.010. Epub 2017 May 31. Enferm Infecc Microbiol Clin (Engl Ed). 2018. PMID: 28579014 English, Spanish.
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*. Gatell JM, et al. Among authors: masia m. AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675. AIDS. 2017. PMID: 29112070 Free PMC article. Clinical Trial.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Among authors: masia m. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Rodger AJ, et al. Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2. Lancet. 2019. PMID: 31056293 Free PMC article.
380 results